Tipifarnib
KO-TIP-002
Phase 2 small_molecule completed
Quick answer
Tipifarnib for Relapsed or Refractory Peripheral T-Cell Lymphoma is a Phase 2 program (small_molecule) at Kura Oncology with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kura Oncology
- Indication
- Relapsed or Refractory Peripheral T-Cell Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed